Blueprint Medicines Corporation

BPMC Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government
Ownership

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
BPMC Income Statement
BPMC Balance Sheet
BPMC Cash Flow
Congress Trading

Recent trades of BPMC by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
BPMC Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
BPMC Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
BPMC Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by BPMC's directors and management

Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
Corporate Lobbying

Estimated quarterly lobbying spending

Quiver Logo

No Corporate Lobbying data for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Crystalline forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making Aug. 13, 2024
  • Patent Title: Map4k1 inhibitors Jul. 23, 2024
  • Patent Title: Crystalline forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making Jun. 04, 2024
  • Patent Title: Cdk2 inhibitors Apr. 30, 2024
  • Patent Title: Crystalline forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1- f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making Apr. 23, 2024
  • Patent Title: Cdk2 inhibitors Mar. 19, 2024
  • Patent Title: Ret inhibitor for use in treating cancer having a ret alteration Jan. 16, 2024
  • Patent Title: Compositions useful for treating disorders related to kit Nov. 28, 2023
  • Patent Title: Egfr inhibitors Aug. 08, 2023
  • Patent Title: Inhibitors of activin receptor-like kinase Apr. 25, 2023
  • Patent Title: Map4k1 inhibitors Dec. 27, 2022
  • Patent Title: Inhibitors of ret Mar. 22, 2022
  • Patent Title: Ret inhibitor for use in treating cancer having a ret alteration Mar. 15, 2022
  • Patent Title: Prkc fusions Mar. 01, 2022
  • Patent Title: Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase Feb. 01, 2022
  • Patent Title: Compounds and compositions useful for treating disorders related to ntrk Jul. 13, 2021
  • Patent Title: Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to kit and pdgfr Jun. 22, 2021
  • Patent Title: Pik3c2g fusions Dec. 29, 2020
  • Patent Title: Inhibitors of the fibroblast growth factor receptor Dec. 29, 2020
  • Patent Title: Compositions and methods for treating kit- and pdgfra-mediated diseases Nov. 10, 2020
  • Patent Title: Compositions useful for treating disorders related to kit Oct. 20, 2020
  • Patent Title: 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors Sep. 15, 2020
  • Patent Title: Pik3ca fusions Jun. 02, 2020
  • Patent Title: Inhibitors of activin receptor-like kinase Jun. 02, 2020
  • Patent Title: Inhibitors of ret Mar. 10, 2020
  • Patent Title: Ntrk2 fusions Sep. 10, 2019
  • Patent Title: Raf1 fusions Aug. 13, 2019
  • Patent Title: Fgr fusions Aug. 06, 2019
  • Patent Title: Prkc fusions Aug. 06, 2019
  • Patent Title: Tert fusions Aug. 06, 2019
  • Patent Title: Compounds and compositions useful for treating disorders related to ntrk Aug. 06, 2019
  • Patent Title: Method for detection of a tecr:pkn1 or an anxa4:pkn1 gene fusion Apr. 02, 2019
  • Patent Title: Inhibitors of activin receptor-like kinase Mar. 19, 2019
  • Patent Title: Compounds useful for treating disorders related to ret Mar. 12, 2019
  • Patent Title: Inhibitors of the fibroblast growth factor receptor Mar. 05, 2019
  • Patent Title: 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors Feb. 12, 2019
  • Patent Title: Inhibitors of the fibroblast growth factor receptor Feb. 05, 2019
  • Patent Title: Inhibitors of ret Jan. 22, 2019
  • Patent Title: Compounds useful for treating disorders related to ret Jul. 31, 2018
  • Patent Title: Inhibitors of ret Jul. 24, 2018
  • Patent Title: Compounds and compositions useful for treating disorders related to ntrk Jul. 10, 2018
  • Patent Title: Compositions useful for treating disorders related to kit and pdgfr Jun. 19, 2018
  • Patent Title: Inhibitors of the fibroblast growth factor receptor Jun. 19, 2018
  • Patent Title: Compositions useful for treating disorders related to kit Jun. 12, 2018
  • Patent Title: Compositions useful for treating disorders related to kit Jun. 12, 2018
  • Patent Title: Compositions useful for treating disorders related to kit Apr. 17, 2018
  • Patent Title: Compositions useful for treating disorders related to kit Feb. 06, 2018
  • Patent Title: Inhibitors of the fibroblast growth factor receptor Jul. 04, 2017
  • Patent Title: Compositions useful for treating disorders related to kit Jun. 27, 2017
  • Patent Title: Compositions useful for treating disorders related to kit Nov. 22, 2016
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
Government Contracts

Estimated quarterly amount awarded from public contracts

Quiver Logo

No recent Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of BPMC in WallStreetBets Daily Discussion

BPMC News

Recent insights relating to BPMC

CNBC Recommendations

Recent picks made for BPMC stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in BPMC

BPMC Top Shareholders
Shareholder
Shares Held
BPMC Options Owners
Shareholder
Security
Underlying Shares

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

BPMC Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view BPMC Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top